Drug intelligence / Profile preview

BAY86-6150

Development stage: Phase 1
Lead developer: Bayer
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

BAY86-6150 is a recombinant Factor VIIa (FVIIa) variant developed by Bayer. It is being investigated for the treatment of bleeding episodes in individuals with moderate or severe congenital hemophilia A or B, both with and without inhibitors. The drug is administered intravenously and functions by promoting blood clotting, acting as a bypassing agent to restore hemostasis in patients where natural clotting factors are deficient or inhibited.

Other names: BAY Factor VII (BAY86-6150)

Targets

Tissue factor/factor viia complex

Beyond the preview

Go deeper on BAY86-6150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY86-6150.

Explore the full profile